Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Airway inflammation in asthma: current and future targets and therapies

N. Hanania
Breathe 2010 6: 245-252; DOI: 10.1183/18106838.0603.245
N. Hanania
Section of Pulmonary and Critical, Care, Asthma Clinical Research Centre, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77478, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hanania@bcm.tmc.edu
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Educational aims

  1. To provide an overview of airway inflammation in asthma.

  2. To review current management guidelines' recommendations for the use of anti-inflammatory therapies in asthma.

  3. To discuss current treatment options for airway inflammation in asthma.

  4. To outline unmet needs for treating airway inflammation in asthma.

  5. To describe novel targets for treating airway inflammation in asthma based on current knowledge.

Summary Asthma is a chronic inflammatory disease of the airways that requires long-term anti-inflammatory therapy. Inhaled corticosteroids (ICS) are recommended for first-line treatment of persistent disease, but not all patients achieve asthma control even when these agents are used in high doses and in combination with other medications, such as a long-acting β2-agonist (LABA) or a leukotriene modifier. Such patients may require additional therapy. As information about asthma pathophysiology and inflammatory phenotypes continues to accumulate, and additional anti-inflammatory options become available, it may be possible to target anti-inflammatory therapy to various aspects of the disease and consequently to improve treatment of patients who respond inadequately to standard ICS-based therapy. Several novel anti-inflammatory therapies are at different stages of clinical development. This article will provide an overview of current and future approaches targeting airway inflammation in asthma.

  • ERS
PreviousNext
Back to top
Vol 6 Issue 3 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Airway inflammation in asthma: current and future targets and therapies
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Airway inflammation in asthma: current and future targets and therapies
N. Hanania
Breathe Mar 2010, 6 (3) 245-252; DOI: 10.1183/18106838.0603.245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Airway inflammation in asthma: current and future targets and therapies
N. Hanania
Breathe Mar 2010, 6 (3) 245-252; DOI: 10.1183/18106838.0603.245
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Epidemiology, occupational and environmental lung disease
  • Mechanisms of lung disease
  • Pulmonary pharmacology and therapeutics
  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • A clinicians’ review of the respiratory microbiome
  • The problems of cohort studies
  • Breathing exercises for asthma
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society